CHDR, ERG, and Lotus Partner to Launch NeuroKit® in the U.S.
2 June 2025
We are proud to announce the official launch of NeuroKit®, our innovative, portable CNS testing platform, unveiled during the American Society of Clinical Psychopharmacology (ASCP) congress in Phoenix.
CHDR is renowned for its data-driven, early-phase clinical trials, with a strong emphasis on pharmacodynamic insights. Building on decades of experience with our validated NeuroCart®, the NeuroKit® now brings the same high-quality testing to external research sites worldwide.
As part of a strategic partnership with Evolution Research Group and Lotus Clinical Research, LLC, NeuroKit® is being piloted at ERG’s Phase 1 unit in Miami. Clinical teams from ERG and Lotus are undergoing extensive training to ensure consistency and data integrity across sites. This collaboration marks the first U.S. deployment of NeuroKit®, with studies set to initiate later in 2025.
This milestone advances CHDR’s mission to make CNS pharmacodynamic testing more accessible across regions. We’re excited to begin this next chapter in collaboration with ERG and Lotus, and to support our partners with critical early insights into CNS drug effects.
Watch the NeuroKit® in action here or explore more here.